

Welcome to DialogClassic Web(tm)

Dialog level 05.07.12D
Last logoff: 13oct05 12:58:20
Logon file001 17oct05 15:47:52
*** ANNOUNCEMENT ***

--UPDATED: Important Notice to Freelance Authors--
See HELP FREELANCE for more information

NEW FILES RELEASED
***Inspec (File 202)
***Physical Education Index (File 138)
***Computer and Information Systems Abstracts (File 56)
***Electronics and Communications Abstracts (File 57)
***Solid State and Superconductivity Abstracts (File 68)
***ANTE: Abstracts in New Technologies (File 60)

RESUMED UPDATING
***ERIC (File 1)

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), and Derwent Chemistry Resource (F355).

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<< >>> of new databases, price changes, e

KWIC is set to 50.

HIGHLIGHT set on as ''

* * . *

File 1:ERIC 1966-2005/Sep 30
(c) format only 2005 Dialog
***File 1: The database is now current with Monthly Updates.**

Set	Items	Description
Cost	is in DialUnits	
?		
B 155, 159, 5, 73		
17oct05 15:48:10	User259876	Session D809.1
\$0.79	0.227	DialUnits File1
\$0.79	Estimated cost	File1
\$0.08	INTERNET	
\$0.87	Estimated cost	this search
\$0.87	Estimated total session cost	0.227 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 155:MEDLINE(R) 1951-2005/Oct 17
(c) format only 2005 Dialog
File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog
***File 159: Cancerlit is no longer updating.**

Please see HELP NEWS159.
File 5:Bioisis Previews(R) 1969-2005/Oct W2
(c) 2005 BIOSIS
File 73:EMBASE 1974-2005/Oct 17
(c) 2005 Elsevier Science B.V.

Set	Items	Description
?		
S (ANGIOTENSIN (W) CONVERTING (W) ENZYME) (S) (ANTIBODY)		
225971	ANGIOTENSIN	
124092	CONVERTING	
2138260	ENZYME	
1382103	ANTIBODY	
S1 841	(ANGIOTENSIN (W) CONVERTING (W) ENZYME) (S) (ANTIBODY)	

?

S S1 OR (MAB (W) 9B9)
841 S1
90102 MAB

103 9B9
45 MAB(W)9B9
S2 852 S1 OR (MAB (W) 9B9)
?

S S2 AND (VECTOR OR ADENOVIRUS OR ADENOVIRAL)
852 S2
309084 VECTOR
88114 ADENOVIRUS
21436 ADENOVIRAL
S3 12 S2 AND (VECTOR OR ADENOVIRUS OR ADENOVIRAL)
?

S S3 AND (BI (W) SPECIFIC (W) ANTIBODY)
12 S3
720509 BI
3004379 SPECIFIC
1382103 ANTIBODY
68 BI(W)SPECIFIC(W)ANTIBODY
S4 0 S3 AND (BI (W) SPECIFIC (W) ANTIBODY)
?

S S3 AND (ANTI (W) AD5 (W) KNOB)
12 S3
1475905 ANTI
4045 AD5
3191 KNOB
0 ANTI(W)AD5(W)KNOB
S5 0 S3 AND (ANTI (W) AD5 (W) KNOB)
?

S S3 AND ("1D6.14" OR "D6.14")
12 S3
0 1D6.14
0 D6.14
S6 0 S3 AND ("1D6.14" OR "D6.14")
?

RD S3
...completed examining records
S7 7 RD S3 (unique items)
?

T S7/3,K/ALL

7/3,K/1 (Item 1 from file: 155)
DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 Dialog. All rts. reserv.

18358305 PMID: 16043100
Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats.
Miller William H; Brosnan M Julia; Graham Delyth; Nicol Campbell G; Morecroft Ian; Channon Keith M; Danilov Sergei M; Reynolds Paul N; Baker Andrew H; Dominiczak Anna F
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G11 6NT, Scotland, UK.
Molecular therapy - the journal of the American Society of Gene Therapy (United States) Aug 2005, 12 (2) p321-7, ISSN 1525-0016
Journal Code: 100890581
Contract/Grant No.: R01 HL 67962-01; HL; NHLBI; Wellcome Trust
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: In Process

Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats.

Local adenoviral (Ad)-mediated gene transfer to the carotid artery of the stroke-prone spontaneously hypertensive rat (SHRSP) is successful in improving endothelial function. Here we explored...

... potential of systemic delivery of Ad encoding endothelial nitric oxide synthase (AdeNOS) to prevent elevation of blood pressure in the SHRSP using both nontargeted and **vector** targeting approaches. Systemic administration of nontargeted AdeNOS failed to modify the rise in blood pressure in SHRSP when administered during the 12th week of age...

... Ad by the liver. Rerouting Ad transduction using a bispecific antibody (anti-ACE/anti-Ad capsid, Fab9B9) that blocks Ad binding to the coxsackie and **adenovirus** receptor and simultaneously retargets AdeNOS to the **angiotensin - converting enzyme** resulted in efficient eNOS overexpression in the lung vasculature and a sustained hypotensive effect (n = 5, P = 0.007, F = 7.9). This study highlights the importance of **vector** targeting to achieve therapeutic gain and represents the first such study in cardiovascular gene therapy.

7/3,K/2 (Item 2 from file: 155)
DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 Dialog. All rts. reserv.

13139234 PMID: 11124057
A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.
Reynolds P N; Zinn K R; Gavrilyuk V D; Balyasnikova I V; Rogers B E; Buchsbaum D J; Wang M H; Miletich D J; Grizzle W E; Douglas J T; Danilov S M; Curiel D T
Division of Human Gene Therapy, University of Illinois at Chicago, Birmingham, Alabama, 35294-3300, USA.
Molecular therapy - the journal of the American Society of Gene Therapy (UNITED STATES) Dec 2000, 2 (6) p562-78, ISSN 1525-0016
Journal Code: 100890581
Contract/Grant No.: CA74242; CA; NCI; HL50255; HL; NHLBI; NOI CO-97110; CO; NCI
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo.

Adenoviral (Ad) vectors are promising gene therapy vehicles due to their in vivo stability and efficiency, but their potential utility is compromised by their restricted tropism. Targeting strategies have been devised to improve the efficacy of these agents, but specific targeting following in vivo systemic administration of **vector** has not previously been demonstrated. The distinct aim of the current study was to determine whether an Ad-targeting strategy could maintain fidelity upon systemic vascular administration. We used a bispecific antibody to target Ad infection specifically to **angiotensin - converting enzyme** (ACE), which is preferentially expressed on pulmonary capillary endothelium and which may thus enable gene therapy for pulmonary vascular disease. Cell-specific gene delivery to ACE-expressing cells was first confirmed in vitro. Administration of retargeted **vector** complex via tail vein injection into rats resulted in at least a 20-fold increase in both Ad DNA localization and luciferase transgene expression in the lungs, compared to the untargeted **vector**. Furthermore, targeting led to reduced transgene expression in nontarget organs, especially the liver, where the reduction was over 80%. Immunohistochemical and immunoelectron microscopy analysis confirmed...

... confirmed using a new noninvasive imaging technique. This study shows that a retargeting approach can indeed specifically modify the gene delivery properties of an Ad **vector** given systemically and thus has encouraging implications for the further development of targetable, injectable Ad vectors.

7/3,K/3 (Item 3 from file: 155)
DIALOG(R)File 155: MEDLINE(R)
(c) format only 2005 Dialog. All rts. reserv.

09334738 PMID: 1846655
Lung is the target organ for a monoclonal antibody to angiotensin - converting enzyme .

Danilov S M; Muzykantov V R; Martynov A V; Atochina E N; Sakharov IYu;
Trakht I N; Smirnov V N
Institute of Experimental Cardiology, USSR Cardiology Research Center,
Moscow.

Laboratory investigation; a journal of technical methods and pathology (UNITED STATES) Jan 1991, 64 (1) p118-24, ISSN 0023-6837

Journal Code: 0376617

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Lung is the target organ for a monoclonal antibody to angiotensin - converting enzyme .

125I-labeled mouse monoclonal antibody (MoAb) to human **angiotensin - converting enzyme** (ACE), termed 9B9 and cross-reacting with rat and monkey ACE, when injected into the circulation, accumulates in the lung in up to 10 to...

...was well tolerated by rats even at very high doses (up to 300 mg/kg/body weight). At the same time, the administration of this **antibody** (which does not inhibit the catalytic activity of ACE) resulted in both a 3-fold decrease of the lung ACE activity and an increase in the activity of serum ACE. The highly organ-specific, nondamaging accumulation of the MoAb 9B9 makes it a promising **vector** for targeted drug delivery to the lung, for modeling of lung pathology, and for gamma-scintigraphic visualization of the lung vascular bed. We also suggest...

7/3,K/4 (Item 4 from file: 155)

DIALOG(R)File 155: MEDLINE(R)

(c) format only 2005 Dialog. All rts. reserv.

08630705 PMID: 2543825

Monoclonal antibodies to angiotensin-converting enzyme: a powerful tool for lung and vessel studies.

Danilov S; Sakharov I; Martynov A; Faerman A; Muzykantov V; Klibanov A; Trakht I
Institute of Experimental Cardiology, Academy of Medical Sciences, Moscow, USSR.

Journal of molecular and cellular cardiology (ENGLAND) Feb 1989, 21 Suppl 1 p165-70, ISSN 0022-2828 Journal Code: 0262322

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

... with high specificity in the lungs as compared with either normal mouse IgG or other organs and blood. The highly specific and nontoxic accumulation of **Mab 9B9** suggests that it also may be used for gamma scintigraphy visualization of the pulmonary vascular bed, detection of lung injury and as a **vector** for targeted drug delivery to the lung.

7/3,K/5 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0015448617 BIOSIS NO.: 200510143117

Selective rat lung endothelial targeting with a new set of monoclonal antibodies to angiotensin I-converting enzyme

AUTHOR: Balyasnikova Irina V; Metzger Roman; Visintine David J; Dimasius Vidas; Sun Zhu-Li; Berestetskaya Yuliya V; McDonald Timothy D; Curiel David T; Minshall Richard D; Danilov Sergei M (Reprint)

AUTHOR ADDRESS: Univ Illinois, Dept Anesthesiol, Anesthesiol Res Ctr, 1819 W Polk St, M-C 519, Chicago, IL 60612 USA**USA

AUTHOR E-MAIL ADDRESS: danilov@uic.edu

JOURNAL: Pulmonary Pharmacology & Therapeutics 18 (4): p251-267 05 2005

ISSN: 1094-5539

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: We demonstrated previously that monoclonal antibody (mAb) 9B9 to **angiotensin - converting enzyme** (ACE) accumulates selectively in the rat lung after systemic injection and thus is a powerful tool for immunotargeting therapeutic agents/genes to the lung microvasculature...

DESCRIPTORS:

ORGANISMS: **Adenovirus** (Adenoviridae...)

...gene **vector** ;

7/3,K/6 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014781532 BIOSIS NO.: 200400148193

Arg-Pro-Pro-Gly-Phe binds to the exodomain of human protease activated receptor 4 (PAR4) to prevent thrombin proteolysis and platelet activation.

AUTHOR: Schmaier Alvin H (Reprint); Pagan-Ramos Eileen; Warnock Mark (Reprint); Krijanovski Yelena (Reprint); Hasan Ahmed A K; Nieman Marvin T (Reprint)

AUTHOR ADDRESS: Internal Medicine, University of Michigan, Ann Arbor, MI, USA**USA

JOURNAL: Blood 102 (11): p776a-777a November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...**ABSTRACT:** does not block binding. CDNA of human PAR4 from Gly19-Arg78 was prepared from HEL cell mRNA by RT-PCR and cloned into Novagen pET19b vector . Recombinant PAR4 exodomain (rPAR4ec) is 15 kDa protein on SDS-PAGE. It is recognized by polyclonal antibody to PAR4, but not to antibodies to PAR1 or PAR3. Biotin-RPPGF specifically binds to rPAR4ec linked to microtiter plates. This binding is blocked by...

7/3,K/7 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0007593257 BIOSIS NO.: 199141105883

ANTI-ACE ANTIBODY AS A VECTOR FOR DRUG TARGETING

AUTHOR: DANILOV S M (Reprint); MARTYNOV A; KLIBANOV A; BOGDANOV A; TORCHILIN V; MUZYKANTOV V R; IDELSON G; ATOCHINA E; TRAKHT I

AUTHOR ADDRESS: INST EXP CARDIOL, USSR CARDIOL RES CENT, MOSCOW 121552, USSR**USSR

JOURNAL: International Journal of Radiation Biology 60 (1-2): p24 1991

CONFERENCE/MEETING: 16TH L. H. GRAY CONFERENCE ON VASCULATURE AS A TARGET FOR ANTI-CANCER THERAPY, MANCHESTER, ENGLAND, UK, SEPTEMBER 17-21, 1990.

INT J RADIAT BIOL.

ISSN: 0955-3002

DOCUMENT TYPE: Meeting

RECORD TYPE: Citation

LANGUAGE: ENGLISH

ANTI-ACE ANTIBODY AS A VECTOR FOR DRUG TARGETING

DESCRIPTORS: ABSTRACT HUMAN RAT HAMSTER MONKEY FELINE MOUSE 9B9 MONOCLONAL ANTIBODY DOXORUBICIN ANTI NEOPLASTIC AGENT **ANGIOTENSIN CONVERTING ENZYME** LUNG ENDOTHELIUM

?

Set	Items	Description
S1	841	(ANGIOTENSIN (W) CONVERTING (W) ENZYME) (S) (ANTIBODY)
S2	852	S1 OR (MAB (W) 9B9)
S3	12	S2 AND (VECTOR OR ADENOVIRUS OR ADENOVIRAL)
S4	0	S3 AND (BI (W) SPECIFIC (W) ANTIBODY)
S5	0	S3 AND (ANTI (W) AD5 (W) KNOB)
S6	0	S3 AND ("1D6.14" OR "D6.14")
S7	7	RD S3 (unique items)

?
S S7 AND (TISSUE (W) SPECIFIC (W) PROMOTER)
 7 S7
 2960799 TISSUE
 3004379 SPECIFIC
 366171 PROMOTER
 678 TISSUE(W)SPECIFIC(W)PROMOTER
S8 0 S7 AND (TISSUE (W) SPECIFIC (W) PROMOTER)

?

Set	Items	Description
S1	841	(ANGIOTENSIN (W) CONVERTING (W) ENZYME) (S) (ANTIBODY)
S2	852	S1 OR (MAB (W) 9B9)
S3	12	S2 AND (VECTOR OR ADENOVIRUS OR ADENOVIRAL)
S4	0	S3 AND (BI (W) SPECIFIC (W) ANTIBODY)
S5	0	S3 AND (ANTI (W) AD5 (W) KNOB)
S6	0	S3 AND ("1D6.14" OR "D6.14")
S7	7	RD S3 (unique items)
S8	0	S7 AND (TISSUE (W) SPECIFIC (W) PROMOTER)

?

COST

17oct05 15:58:25 User259876 Session D809.2
\$3.04 0.895 DialUnits File155
 \$0.88 4 Type(s) in Format 3
 \$0.88 4 Types
\$3.92 Estimated cost File155
 \$0.71 0.227 DialUnits File159
\$0.71 Estimated cost File159
 \$5.35 0.908 DialUnits File5
 \$0.48 3 Type(s) in Format 95 (KWIC)
 \$0.48 3 Types
\$5.83 Estimated cost File5
 \$6.10 0.573 DialUnits File73
\$6.10 Estimated cost File73
 OneSearch, 4 files, 2.603 DialUnits FileOS
\$2.93 INTERNET
\$19.49 Estimated cost this search
\$20.36 Estimated total session cost 2.830 DialUnits

?

[Return to logon page!](#)

Refine Search**Search Results -**

Term	Documents
9B9	51
9B9S	1
"1D6.14"	21
1D6.14S	0
"D6.14"	4
D6.14S	0
((D6.14" OR "1D6.14") SAME 9B9).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	2
((9B9") SAME ("1D6.14" OR "D6.14")).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	2

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L10

**Refine Search****Recall Text****Clear****Interrupt****Search History****DATE:** Monday, October 17, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
			result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=AND</i>			
<u>L10</u>	("9B9") same ("1D6.14" or "D6.14")	2	<u>L10</u>
<u>L9</u>	L7 and ((tissue adj specific) adj promoter)	2	<u>L9</u>
<u>L8</u>	L7 and ((anti-Ad5 adj knob) or ("1D6.14"))	1	<u>L8</u>
<u>L7</u>	L6 and L5	28	<u>L7</u>
<u>L6</u>	(bispecific or bi-specific) adj antibody	6470	<u>L6</u>
<u>L5</u>	L4 and (adenovirus or adenoviral)	127	<u>L5</u>
<u>L4</u>	L3 or ("9B9")	722	<u>L4</u>
<u>L3</u>	((angiotensin adj converting) adj enzyme) same antibody	677	<u>L3</u>
<u>L2</u>	L1 and ((angiotensin adj converting) adj enzyme)	2	<u>L2</u>
<u>L1</u>	Curiel-David-T\$.in.	69	<u>L1</u>

END OF SEARCH HISTORY

 PALM INTRANET

Day : Monday
Date: 10/17/2005
Time: 16:24:56

Inventor Name Search

Enter the first few letters of the Inventor's Last Name.
Additionally, enter the first few letters of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page

 PALM INTRANET

Day : Monday
Date: 10/17/2005
Time: 16:24:56

Inventor Name Search

Enter the first few letters of the Inventor's Last Name.
Additionally, enter the first few letters of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page



PALM INTRANET

Day : Monday
Date: 10/17/2005
Time: 16:24:56

Inventor Name Search

Enter the first few letters of the Inventor's Last Name.
Additionally, enter the first few letters of the Inventor's First name.

Last Name	First Name
Curiel	David

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | Home page